Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 2850 of 3499 entries
View as:

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00644072 Org: User:
Start: 03/07/08 End: 06/16/11 Due: 06/16/12

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Phase: N/A Priority: Normal
NCT ID: NCT01260688 Org: User:
Start: 10/31/10 End: 02/28/14 Due: 02/28/15

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00678769 Org: User:
Start: 05/31/08 End: 10/31/15 Due: 10/31/16

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00066599 Org: User:
Start: 06/30/03 End: 06/30/04 Due: 06/30/05

A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT00001431 Org: User:
Start: 02/28/95 End: 11/30/00 Due: 11/30/01

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01822496 Org: User:
Start: 11/04/13 End: 06/04/18 Due: 06/04/19

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03033576 Org: User:
Start: 10/23/17 End: 03/20/24 Due: 03/20/25

SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT00005862 Org: User:
Start: 10/31/00 End: - Due: -

506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00003837 Org: User:
Start: 09/30/99 End: 11/30/07 Due: 11/30/08

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00017251 Org: User:
Start: 04/30/01 End: - Due: -

Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Phase: N/A Priority: Normal
NCT ID: NCT00301847 Org: User:
Start: 11/30/05 End: - Due: -

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Phase: N/A Priority: Normal
NCT ID: NCT03018288 Org: User:
Start: 09/21/17 End: 12/20/22 Due: 12/20/23

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02503709 Org: User:
Start: 09/30/16 End: 10/09/20 Due: 10/09/21

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01861314 Org: User:
Start: 07/03/13 End: 03/19/26 Due: 03/19/27

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00045201 Org: User:
Start: 06/13/02 End: 08/22/25 Due: 08/22/26

Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00054548 Org: User:
Start: 10/31/02 End: - Due: -

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00059787 Org: User:
Start: 04/30/03 End: 05/31/10 Due: 05/31/11

SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00103311 Org: User:
Start: 01/31/05 End: 09/30/10 Due: 09/30/11

A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations

Phase: N/A Priority: Normal
NCT ID: NCT00001681 Org: User:
Start: 10/31/97 End: 09/30/00 Due: 09/30/01

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

Phase: N/A Priority: Normal
NCT ID: NCT02936752 Org: User:
Start: 06/23/17 End: 02/12/25 Due: 02/12/26

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00576654 Org: User:
Start: 03/18/08 End: 01/16/20 Due: 01/16/21

Sunitinib in Treating Young Patients With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00387920 Org: User:
Start: 10/31/06 End: - Due: -

Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00602277 Org: User:
Start: 04/30/08 End: 08/31/16 Due: 08/31/17

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01624441 Org: User:
Start: 08/21/12 End: 09/10/13 Due: 09/10/14

Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor

Phase: N/A Priority: Normal
NCT ID: NCT04852302 Org: User:
Start: 08/11/21 End: 06/06/24 Due: 06/06/25